Tardive Dyskinesia (TD) | AUSTEDO XR® (deutetrabenazine) …
AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with …
AUSTEDO XR® Medication for Tardive Dyskinesia (TD)
Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.
Austedo (deutetrabenazine): Uses, Side Effects, Dosage Guide
Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) …
Austedo for Uncontrolled Movements in Huntington’s and Tardive Dyskinesia
Jul 16, 2024 · Austedo (aw-STED-oh) was approved in 2017 and is the first medicine approved to treat both tardive dyskinesia and chorea caused by Huntington’s disease.
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR ...
Nov 7, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and …
Austedo XR Approved: A New Treatment Option for Tardive Dyskinesia …
May 30, 2024 · The FDA has approved Austedo XR as a once-daily pill treatment option for tardive dyskinesia and Huntington disease chorea control.
Tardive Dyskinesia Treatment | AUSTEDO XR® (deutetrabenazine)
Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.
Tardive Dyskinesia (TD) Resources | AUSTEDO XR® …
Resources for each step of the treatment journey with AUSTEDO XR Teva is committed to supporting your patients with tardive dyskinesia (TD) and their care partners.
Study Explores Tardive Dyskinesia Outcomes With …
Nov 12, 2024 · It demonstrates real-world treatment patterns and outcomes with once-daily Austedo XR (deutetrabenazine) extended-release tablets and twice-daily Austedo …
Teva Announces FDA Approval of AUSTEDO® XR ... - Teva …
Feb 17, 2023 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis …